Cargando…

One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy

BACKGROUND: Central serous chorioretinopathy (CSC) is characterized by an accumulation of subretinal fluid (SRF) in the macula. It is usually treated by laser photocoagulation or photodynamic therapy (PDT) with consisting of different doses and power. This study aimed to compare the efficacy of half...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichai, Jirarattanasopa, Vanchalerm, Banchasakjaroen, Mansing, Ratanasukon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802284/ https://www.ncbi.nlm.nih.gov/pubmed/33430812 http://dx.doi.org/10.1186/s12886-020-01796-0

Ejemplares similares

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
por: Ratanasukon, Mansing, et al.
Publicado: (2013)

High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
por: Ratanasukon, Mansing, et al.
Publicado: (2012)

Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Naseripour, Masood, et al.
Publicado: (2016)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
por: Servillo, Andrea, et al.
Publicado: (2023)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita, Kyoko, et al.
Publicado: (2012)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Alovisi, Camilla, et al.
Publicado: (2020)

Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)
por: Bhurayanontachai, Patama, et al.
Publicado: (2011)

Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
por: Ratanasukon, Mansing, et al.
Publicado: (2018)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
por: Atik, Alp, et al.
Publicado: (2017)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
por: Horiguchi, Etsuyo, et al.
Publicado: (2022)

The Impact of Vision Impairment (IVI) Questionnaire; Validation of the Thai-Version and the Implementation on Vision-Related Quality of Life in Thai Rural Community
por: Ratanasukon, Mansing, et al.
Publicado: (2016)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Kinoshita, Takamasa, et al.
Publicado: (2016)

Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Nassisi, Marco, et al.
Publicado: (2017)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report
por: Zhang, Zhengwei, et al.
Publicado: (2021)

Surgical outcomes and prognostic factors following vitrectomy in acquired immune deficiency syndrome patients with cytomegalovirus retinitis-related retinal detachment
por: Sittivarakul, Wantanee, et al.
Publicado: (2020)

Results of intravitreal dexamethasone implant (Ozurdex(®)) for retinal vascular diseases with macular edema: An observational study of real-life situations
por: Jirarattanasopa, Pichai, et al.
Publicado: (2022)

Visual outcomes of early and late vitrectomy for breakthrough vitreous hemorrhage associated with exudative age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jirarattanasopa, Pichai, et al.
Publicado: (2023)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011)

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy
por: Yu, Jia, et al.
Publicado: (2019)

Effect of half adult dose of oral Rifampicin (300mg) in patients with idiopathic central serous chorioretinopathy
por: Khan, Muhammad Saim, et al.
Publicado: (2016)

Low-dose aspirin as treatment for central serous chorioretinopathy
por: Caccavale, Antonio, et al.
Publicado: (2010)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study
por: Haga, Fuminori, et al.
Publicado: (2017)

Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography
por: Liu, Juejun, et al.
Publicado: (2020)

Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report
por: Liu, Yang, et al.
Publicado: (2019)

Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy
por: Yang, Hyun Seung, et al.
Publicado: (2020)

Correction to: Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography
por: Liu, Juejun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jm3v4fnep4vqmi0kf82h7otik0